The iCAN club membership enables not only a platform for interacting but also an opportunity for developing areas of mutual interest potentially leading to in-depth partnerships. Indeed, a concrete project to use novel anonymization techniques in secondary use of healthcare data from more than one health care provider is already in development.
VEIL.AI is a spin-out from Institute for Molecular Medicine Finland FIMM and is specialized in anonymization services and synthetic data. VEIL.AI technologies and services help to utilize sensitive health data for research, innovation and development to support new discoveries, patient treatment and better decision making in healthcare. VEIL.AI is committed to safeguarding the privacy of individuals while maintaining data richness and maximum utility.
“We are thrilled to join the iCAN community”, says CEO Tuomo Pentikäinen. “The iCAN club offers a great venue to envision new ways to utilize sensitive health data. iCAN also offers us R&D opportunities to develop and showcase the potential of advanced data anonymization technologies.” Pentikäinen notes that Finland is currently building the structures and policies on how to balance the utility of health data with the protection of individual privacy. “These two extremely important aims can be combined with new technologies. iCAN offers a cutting-edge environment to explore and evaluate the choices and opportunities we have in Finland”, he says.
“iCAN’s strength lies in integrating molecular and digital health data with the patient in the focus. iCAN provides a lot of opportunities for our private partners for discoveries and developing solutions in the digital health, diagnostic, and therapeutic space. It is great to have VEIL.AI join the iCAN Club to develop our joint interests. The goal of the Finnish R&D flagships is to provide impact through increased public-private partnerships, and for iCAN we hope this to include both large flagship partnerships with larger companies as well as co-creation with startups and SMEs” notes iCAN Executive Officer Tomi Mäkelä.
iCAN - Digital Precision Cancer Medicine Flagship
Ilona Kotala, Business Development, Ilona.email@example.com, 040-5357 830
Kimmo Pitkänen, Account Director, Kimmo.firstname.lastname@example.org, 050 587 4003